HedgeChatter

  • Home /
  • Tag Archives

stock

8:36 am Real Goods Solar will change the ticker symbol for its Class A common stock listed on the NASDAQ Capital Market from RSOL to RGSE, effective upon market open on Monday, Feb 24, 2014

moreView todays social media effects on RSOLView the latest stocks trending across Twitter. Click to view dashboardSee who Real is hiring next, click here to view […]

February 21, 2014 Bystocknews , Comments Off on 8:36 am Real Goods Solar will change the ticker symbol for its Class A common stock listed on the NASDAQ Capital Market from RSOL to RGSE, effective upon market open on Monday, Feb 24, 2014 read more

8:07 am Charter Comm beats by $0.07

moreView todays social media effects on CHTRView the latest stocks trending across Twitter. Click to view dashboardSee who Charter is hiring next, click here to view […]

February 21, 2014 Bystocknews , Comments Off on 8:07 am Charter Comm beats by $0.07 read more

8:49 am XL Capital Board increases share buyback program, authorizing the co to buy back up to $1 bln of its ordinary shares; increases quarterly dividend to $0.16 per share from $0.14 per share

moreView todays social media effects on XLView the latest stocks trending across Twitter. Click to view dashboardSee who XL is hiring next, click here to view […]

February 21, 2014 Bystocknews , Comments Off on 8:49 am XL Capital Board increases share buyback program, authorizing the co to buy back up to $1 bln of its ordinary shares; increases quarterly dividend to $0.16 per share from $0.14 per share read more

8:14 am Epizyme announces publication of preclinical data demonstrating clinical candidate EPZ-6438 as potent and selective inhibitor of EZH2 in genetically defined non-Hodgkin lymphoma; preclinical study results published in the Journal Mo

moreView todays social media effects on EPZMView the latest stocks trending across Twitter. Click to view dashboardSee who Epizyme is hiring next, click here to view […]

February 21, 2014 Bystocknews , Comments Off on 8:14 am Epizyme announces publication of preclinical data demonstrating clinical candidate EPZ-6438 as potent and selective inhibitor of EZH2 in genetically defined non-Hodgkin lymphoma; preclinical study results published in the Journal Mo read more